ZYCUBO® (copper histidinate), First FDA-Approved Treatment for Patients with Menkes Disease, Exclusively Available at Biologics by McKesson in the United States
Cary, N.C. , Jan. 13, 2026 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease […]
Biologics by McKesson’s Pharmacy Elite™ Selected as Hub for Rigel Pharmaceuticals’ Tavalisse®, Gavreto® and Rezlidhia®
Cary, N.C. , Jan. 2, 2026 – Biologics by McKesson’s Pharmacy Elite™, has been awarded the Rigel Pharmaceuticals Hub contract […]
AQVESME® (mitapivat), FDA-Approved for Adults with Thalassemia, Exclusively Available at Biologics by McKesson
Cary, N.C. , Dec. 29, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology, cell and gene, […]
KOMZIFTI® (ziftomenib), FDA-Approved for Treatment of Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia, Available at Biologics by McKesson
Cary, N.C. , Nov. 13, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease […]
INLURIYO™ (imlunestrant) FDA-Approved for Treatment of ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer, Available at Biologics by McKesson
Cary, N.C. , Oct. 1, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease […]
PALSONIFY™ (paltusotine), FDA-Approved for Treatment of Adults with Acromegaly Who Had an Inadequate Response to Surgery and/or for Whom Surgery Is Not an Option, Available at Biologics by McKesson
Cary, N.C. , Sept. 25, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease […]
Precigen Selects McKesson to Support Specialty Pharmacy and Patient Hub Services for Launch of Novel Immunotherapy
CARY, N.C., Sept. 25, 2025 – Biologics by McKesson, in partnership with Inspirogene by McKesson, has been chosen by Precigen […]
InspiroGene by McKesson Selected as the Specialty Pharmacy Partner for Iovance’s Amtagvi®—First Cell Therapy Approved for Solid Tumors
CARY, N.C., Sept. 24, 2025 – Biologics by McKesson is proud to announce the launch of Amtagvi® (lifileucel), the newest […]
WAYRILZ™ (rilzabrutinib), FDA-Approved for Treatment of Adults with Immune Thrombocytopenia, Available at Biologics by McKesson
Cary, N.C. , Sept. 10, 2025 – Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease […]
PIQRAY® (alpelisib) FDA Approved for the Treatment of Patients with a PIK3CA Mutation in HR+/HER2- Advanced Breast Cancer , Available Exclusively at Biologics by McKesson
Cary, N.C., August 7, 2025 – Effective June 15, PIQRAY® (alpelisib) is now exclusively available at Biologics by McKesson, an […]